Size, Growth and Competitivelandscapeaa

Autoimmune Disease Treatment Market TrendsOverview by Share, Size, Growth and Competitive landscape

Autoimmune Disease Treatment Market Overview

Market Research Future (MRFR)'s latestassessment reveals that the global autoimmunedisease treatment market share is expected to thriveat Steady CAGR during the forecast period. Themarket signifies massive unmet needs for diagnosis. It is projected to favor the expansion of the global market by bringing advanced, precise and effectivedrugs and treatments.

Definite causes for the development of autoimmunediseases have not been identified. Thus, the emphasis is on the early diagnosis of the disease. Increasing awareness coupled with large-scale prevalence is likely to aid the proliferation of the <u>Autoimmune Disease Treatment Market trends</u> in the foreseeable future.


Expenditures for the treatment of these diseases are on the rise and is poised to exhibit a similar trend in the forthcoming years. As per the National Institutes of Health (NIH), the U.S., the healthcare expenditure for autoimmune diseases has reached half of that of the cancer expenditure. Furthermore, the introduction of favorable policies for insurance reimbursements are anticipated to augment the market over the next couple of years. However, factors such as side effects, counterfeit drugs, and expensiveness of the treatment are forecasted to check the expansion of the autoimmune disease treatment market across thereview period.

Competitive Dashboard:

Autoimmune Disease Treatment Market Players are Abbott Laboratories, Genentech Inc., Bayer Schering Pharma AG, Amgen Inc., Biogen Idec Inc., Chugai Pharmaceutical Co. Ltd., Danaher, Bio-Rad, Elan Corporation Plc, F. Hoffmann-La Roche AG, Glaxo Smith Kline Plc, HYCOR Biomedical, Eli Lilly and Company, Johnson & Johnson Inc., Siemens, Squibb Company, Merck & Co. Inc., and Thermo Fisher Scientific.

Market Segmentation

By disease type, the global autoimmune disease treatment market has been segmented into localized, and systemic. The localized segment is further sub-segmented into multiple sclerosis, inflammatory bowel disease, diabetes, and other. The systemic segment is sub-segmented into rheumatoid arthritis, psoriasis, lupus, and others.



By therapeutic products, the market has been segmented into drugs and therapeutic andmonitoring equipment. The drugs segment is further sub-segmented into biologics,immunosuppressant, anti-inflammatory drugs, corticosteroids, and non-steroidal anti-inflammatorydrugs.

By distribution channel, the autoimmune disease treatment market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others